A Retrospective Cohort Study of Multiple Immune-Related Adverse Events and Clinical Outcomes Among Patients With Cancer Receiving Immune Checkpoint Inhibitors
Background and Objectives Immune checkpoint inhibitors (ICIs) are effective in various types of cancer and cause immune-related adverse events (irAEs). The occurrence of irAEs is associated with improved survival outcome. We investigated the association between the occurrence of irAEs and overall su...
المؤلفون الرئيسيون: | Hiroki Hata MS, Chikako Matsumura PhD, Yugo Chisaki PhD, Kae Nishioka, Misaki Tokuda, Kazuyo Miyagi, Tomoki Suizu MS, Yoshitaka Yano PhD |
---|---|
التنسيق: | مقال |
اللغة: | English |
منشور في: |
SAGE Publishing
2022-09-01
|
سلاسل: | Cancer Control |
الوصول للمادة أونلاين: | https://doi.org/10.1177/10732748221130576 |
مواد مشابهة
-
Factors Associated With Efficacy and Nivolumab-Related Interstitial Pneumonia in Non-Small Cell Lung Cancer: A Retrospective Survey
حسب: Hiroki Hata MS, وآخرون
منشور في: (2020-12-01) -
Myocardial Vasculitis Associated With the Immune Checkpoint Inhibitor Pembrolizumab
حسب: Hideo Oishi, MD, وآخرون
منشور في: (2020-10-01) -
Cancer Immune Checkpoint Inhibitor Therapy and the Gut Microbiota
حسب: Arthur E. Frankel MD, وآخرون
منشور في: (2019-04-01) -
Desensitizing Effect of Cancer Cachexia on Immune Checkpoint Inhibitors in Patients With Advanced NSCLC
حسب: Taichi Miyawaki, MD, وآخرون
منشور في: (2020-06-01) -
Inflammatory and immune checkpoint markers are associated with the severity of aortic stenosisCentral MessagePerspective
حسب: Bilguun Erkhem-Ochir, MD, وآخرون
منشور في: (2021-03-01)